SLRX — Salarius Pharmaceuticals, Inc.

Summary of Salarius Pharmaceuticals Q2 2022 Earnings Call

1. Key Financial Results and Metrics

• Net Loss: $4.7 million ($0.09 per share) for Q2 2022, compared to $3.1 million ($0.07 per share) in Q2 2021. The increase was attributed to higher operating expenses and lack of grant revenue.
• R&D Expenses: $2.9 million in Q2 2022, up from $2.1 million in Q2 2021, primarily due to spending on targeted protein degradation technology.
• General and Administrative Expenses: Increased to $1.8 million from $1.6 million year-over-year, driven by higher personnel costs.
• Cash Position: As of June 30, 2022, cash and cash equivalents totaled $22.6 million, down from $29.2 million at the end of 2021. This is expected to fund operations into 2023.

2. Strategic Updates and Business Highlights

• Seclidemstat Program: Enrollment in the Phase 1/2 study for Ewing’s and FET-rearranged sarcomas is progressing well, with 15 clinical sites and plans for more. Interim data is expected later this year.
• Collaboration with Volition Rx: This partnership aims to utilize epigenetic profiling to study biomarkers for seclidemstat, enhancing the understanding of drug activity in patients.
• SP-3164 Development: The company is advancing its targeted protein degradation program, with an IND submission planned for the first half of 2023. The pre-IND meeting with the FDA has been completed successfully.

3. Forward Guidance and Outlook

• Salarius anticipates a busy second half of 2022 with multiple data updates from ongoing clinical trials. The company is focused on achieving significant milestones for both seclidemstat and SP-3164.
• Management expressed confidence in the potential of both drug candidates to address high unmet medical needs in cancer treatment.

4. Bad News, Challenges, or Points of Concern

• Increased Net Loss: The rise in net loss and operating expenses could raise concerns about financial sustainability, especially with no grant revenue recorded in 2022 compared to $1.8 million in 2021.
• Dependence on Clinical Data: The success of Salarius's programs heavily relies on upcoming clinical data, which introduces uncertainty regarding the efficacy and market acceptance of their drug candidates.
• Competitive Landscape: The targeted protein degradation field is gaining interest, which may lead to increased competition and pressure to demonstrate superior efficacy and safety.

5. Notable Q&A Insights

• Partnership Implementation: Dr. Daniela Santiesteban provided details on the Volition Rx partnership, indicating that patient samples for epigenetic profiling will be collected towards the end of 2022 and into early 2023.
• Enrollment Status: CEO David Arthur confirmed that enrollment for seclidemstat is progressing well, with interest from additional clinical sites, although specific enrollment numbers were not disclosed.
• IND Enabling Studies for SP-3164: Dr. Santiesteban confirmed that the company is on track for IND submission in early 2023, with ongoing studies to evaluate the drug's mechanism of action and efficacy.

Overall, Salarius Pharmaceuticals is navigating a critical phase in its development pipeline with promising advancements in its drug candidates, although financial losses and the need for successful clinical outcomes remain key challenges.